| Prev Close | 508.31 |
| Open | 513.42 |
| Day Low/High | 509.20 / 518.92 |
| 52 Wk Low/High | 328.12 / 664.64 |
| Volume | 498.17K |
Regeneron Pharmaceuticals, Inc. (REGN)
514.05
5.74
1.13
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 106.71B |
| Market Cap | 54.24B |
| P/E Ratio | 18.63 |
| Div & Yield | N.A. (N.A) |
Regeneron Downtrend Ending But No Rush to Buy
Stock still needs a period of base building to support advance.
12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction
Thanks to the stock market correction many world-class stocks are back down to attractive levels.
Jim Cramer: Stocks Are on Fire For Good Reasons
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
7 Hot Investing Bets to Make in Biotech
These favorite names in the volatile sector offer the potential for high rewards.
Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet
Traders and investors should stand aside until the situation with this biotech name offers a better entry point.
Investors Shun Biotech Stocks
The speed at which investors have bailed on this sector is alarming.
Biotech Stocks to Watch: Part 1
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
Stalking Regeneron for Key Low and Reversal
Many swings on a particular chart tend to be similar to others.
Regeneron Pharmaceuticals Ready to Make All-Time Highs
Shares have regained their 50-day moving average and look likely to push higher.
Cramer: Rotations Hit Companies That Don't Deserve It
Case in point: Home Depot and Lowe's.
Cramer: Stop Talking About the 'Market'
It just isn't as useful or descriptive right now.
Cramer: This Is No Country for Old Value
Down-and-out stocks have become toxic.
Cramer: You Need 2 Monday Morning Game Plans
We really want to shake out the weak hands here.
Cramer: Rally Is Earning Some Trust
The market rally broadened out nicely today.
Charting the Biotechs
Time to revisit some stocks now that biotech has cooled.
Regeneron Shows Green Shoots
Clues in the chart point to higher prices to come.
Cramer: Retail Rally Shows the Perils of Being Too Negative
There's a forest fire in the sector.
Regeneron Is Ready to Rally
An upside breakout appears on the horizon.
Regeneron Could Generate More Upside
Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.
Regeneron Is Ready to Reanimate: Watch for a Breakout
This stock is testing resistance and could push back up to last year's highs.
Cramer: Don't Give the Fed Credit
Most of the 10 best stocks of the bull market did it their way.
Cramer: When a Trump Tweet Is a Buy Signal
Drug companies are the latest targets/beneficiaries.
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Icahn may have a tough time finding interest in this behemoth.
